Jithma P. Abeykoon, M.D.

Contact Us for the Latest Status

• MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor Inhibition in Hematologic Malignancies with Q702, a Small Molecular Inhibitor Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is establish the highest dose of Q702 tested that has acceptable tolerability and safety.

• Phase 2 Trial of Ulixertinib for Patients With Histiocytic Neoplasms Rochester, Minn.

  The purpose of this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.